Navigation Links
InterMune Announces Progress on Pirfenidone in IPF
Date:4/21/2008

- Initiating planned roll-over study for CAPACITY patients in Q3 -

- Patient retention and conduct of Phase 3 CAPACITY program remain

excellent to date - - Abstract of Shionogi Phase 3 pirfenidone study now available on ATS

website -

BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will initiate an open-label roll-over study to evaluate the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). The roll-over study will be open to patients who complete one of the two concurrent Phase 3 CAPACITY studies of pirfenidone in IPF. InterMune expects that the first patient will enter the roll-over study in August 2008. Additional information regarding the design and objectives of the pirfenidone roll-over study will be available at http://www.clinicaltrials.gov within approximately one week. The anticipated 2008 costs of conducting the study are included in InterMune's expense guidance of February 7, 2008.

Regarding the progress of CAPACITY, the company noted that patient retention and overall study conduct remain excellent, with a low rate of patient dropouts to date. InterMune anticipates that top-line results from CAPACITY will be available in January 2009. Data from the CAPACITY trials will remain blinded during the extension study enrollment period.

The company also provided an update on the publication plans of Shionogi concerning its Phase 3 study of pirfenidone in IPF performed in Japan. The abstract of the Tuesday, May 20 presentation by Shionogi of the results of this study at the American Thoraci
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
2. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
3. InterMune Announces Start of Phase 1b Trial of ITMN-191
4. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
5. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
6. Aida Announces New Anti-Cancer Drug Under Development
7. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
8. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
10. ViroPharma Announces Discontinuation of HCV-796 Development
11. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... CARLSBAD, Calif. , May 20, 2013   ... today announced that its Applied Biosystems™ 3500 Dx and ... Federal Commission for Protection against Health Risks in ... marks a major extension of Life Technologies, capabilities to ... America with Sanger -based ...
(Date:5/20/2013)... May 20, 2013 Enrollment of patients with ... 2b dose-finding clinical trial of product candidate NewMet ... treatment for Type 2 diabetes. Elcelyx expects to complete ... in June. Results of the trial,s primary endpoint of ... summer, and the read-out for long-term glucose lowering and ...
(Date:5/20/2013)... , May 20, 2013  Medicare Part ... are overwhelmingly satisfied, citing lower costs, convenient access ... new survey from Hart Research Associates released today ... than 40% of Part D seniors (9.5 million) ... "Seniors like the lower costs, pharmacy ...
Breaking Medicine Technology:Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 2Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2
... Stryker Corporation (NYSE: SYK ) reported operating ... as follows: Fourth Quarter Highlights ... (8.8% increase as reported) to $1,995 million Orthopaedic Implant ... as reported) MedSurg Equipment sales increased 15.4% on a ...
... Calif., Jan. 25, 2011 Most people know that ... why they should take them or which vitamins they ... getting the vitamins they need, the Stater Bros. website ... 5-minute personal health survey.  The recommendations from this survey ...
Cached Medicine Technology:Stryker Reports 9% Sales Growth, 13% Adjusted Net Earnings Growth for Quarter Ended December 31, 2010 2Stryker Reports 9% Sales Growth, 13% Adjusted Net Earnings Growth for Quarter Ended December 31, 2010 3Stryker Reports 9% Sales Growth, 13% Adjusted Net Earnings Growth for Quarter Ended December 31, 2010 4Stryker Reports 9% Sales Growth, 13% Adjusted Net Earnings Growth for Quarter Ended December 31, 2010 5Stryker Reports 9% Sales Growth, 13% Adjusted Net Earnings Growth for Quarter Ended December 31, 2010 6Stryker Reports 9% Sales Growth, 13% Adjusted Net Earnings Growth for Quarter Ended December 31, 2010 7Stryker Reports 9% Sales Growth, 13% Adjusted Net Earnings Growth for Quarter Ended December 31, 2010 8Stryker Reports 9% Sales Growth, 13% Adjusted Net Earnings Growth for Quarter Ended December 31, 2010 9Stryker Reports 9% Sales Growth, 13% Adjusted Net Earnings Growth for Quarter Ended December 31, 2010 10Stryker Reports 9% Sales Growth, 13% Adjusted Net Earnings Growth for Quarter Ended December 31, 2010 11Stryker Reports 9% Sales Growth, 13% Adjusted Net Earnings Growth for Quarter Ended December 31, 2010 12Stater Bros. Introduces Free Personal Vitamin Recommendation Program 2
(Date:5/21/2013)... The National Resident Matching Program NRMP® ... its Board of Directors. Hal B. Jenson, M.D., ... of Medicine, has been named President. Maria C. ... of California San Diego, is the President-Designate, and Glenn ... Medical Center, is the Secretary-Treasurer. Kenneth B. Simons, ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 The Michigan ... meeting in Lapeer on , June 11th. , Meeting ... Location: Lapeer Regional Medical Center,     Conference Room 5 (Lower ... These meetings are designed to assist people with lupus ... one another, and to get a better understanding of ...
(Date:5/21/2013)... The birth control safety advocates at DrugRisk.com ... the contraceptive NuvaRing. A new report shows the number ... increased in recent months*. , DrugRisk was created to ... the latest safety alerts, recalls, studies and legal news. ... side effects and decide if they need legal advice. ...
(Date:5/20/2013)... (PRWEB) May 21, 2013 USA Book ... Transcendent Approach to Peak Performance" won the top honor ... Category. Chosen over a multitude of international titles ... attention and critical acclaim from both mainstream and new ... - mentally, physically and spiritually. , “The ...
(Date:5/20/2013)... Dallas, Texas (PRWEB) May 21, 2013 ... based on product type into two categories - ... AED market is classified into five categories, namely, ... the market is forecast till 2017. Automated external ... lives of sudden cardiac arrest victims. Considering the ...
Breaking Medicine News(10 mins):Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 2Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 3Health News:DrugRisk Update Shows Increase in NuvaRing Blood Clot Lawsuits 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 3Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 2Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 3
... 9, 2010, describes the discovery of an alternative form of ... sterilize them. Nematodes are among the most abundant, diverse and ... via Symbiosis; Recent Spread of a Drosophila Defensive ... and his colleagues. In a video interview, Jaenike explains the ...
... ... a range of preventable health problems, Sam’s Club is hosting free health screenings in more ... , ... July 8, 2010 -- To help its members and community residents detect a range of ...
... , THURSDAY, July 8 (HealthDay News) -- Scientists report they,ve ... "soldiers" in the immune system that might prevent the AIDS ... researchers, these newly found antibodies connect with and neutralize more ... all major genetic subtypes of the virus. That breadth ...
... provide authors additional time to complete their research, the ... 31 for the Cell Symposia meeting, Influenza: Translating basic ... Marriott Hotel in Washington, DC., Abstracts are invited for ... "Virus biology," "Pandemics, pathogenesis and disease," "Immune response and ...
... . Montreal, July 8, 2010 - A team of ... Cancer (IRIC) of the University of Montreal have identified ... IRIC Principal Investigators Martine Raymond, Alain Verreault and Pierre ... Research Institute of the National Research Council Canada, the ...
... NC Men who have a baseline PSA value of ... up to 11 times more likely to die from prostate ... to Duke University Medical Center researchers. Scientists say ... , supports routine, early prostate-specific antigen (PSA) screening among healthy ...
Cached Medicine News:Health News:Sam's Club Hosts Health Screenings July 10 2Health News:New Anti-HIV Weapons Found in Immune System 2Health News:Cell symposia meeting, Influenza: Translating basic insights, to be held Dec. 2-4, 2010 2Health News:Vitamin B3 as a novel approach to treat fungal infections 2Health News:Baseline PSA predicts risk of death from prostate cancer 2
IR Autoflow Dual Chamber Over-Under Water-Jacketed CO 2 Inc....
... The Dual Media Set, different from ... Broth (LB) or other specially prepared medium, ... OVEREXPRESSION BROTH (OB). For cell expansion, E. ... the production of the recombinant protein is ...
...
0.3% Beef extract, 0.5% Peptone, 0.5 % Lactose....
Medicine Products: